Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure

Boehringer And Lilly 'Urgently' Submitting EMPEROR-Preserved Data

 
• By Kevin Grogan

Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.

Boehringer Ingelheim headquarters in Ingelheim, Germany
Jardiance turning into a megablockbuster for Boehringer Ingelheim • Source: Archive (dieth+schröder-fotografie)

More from Cardiovascular

More from Therapy Areas